Xinhuanet Shanghai, November 6 (Wu Qilong) From November 5 to 10, the 7th China International Import Expo (hereinafter referred to as the "CIIE") was held in Shanghai. As an important platform for my country to promote high-level opening up and promote international trade and investment cooperation, the CIIE has played an active role in promoting the development of the global medical and health industry.

At the same time, the CIIE also focuses on the latest technologies, products and services in the global medical and health field. It has been held for seven consecutive years. It is not only an "accelerator" to promote pharmaceutical innovation and development, but also a vane for the future development of the health industry. As a "full-time student" of the CIIE, Roche, who has "seven appointments to the CIIE", is not only a witness to the development of China's medical and health industry, but also an in-depth participant and beneficiary.

It is reported that as one of the largest exhibitors in the medical devices and medical care exhibition area, Roche has the theme of "Huacai 30, Ju's Future" this year, bringing more than 30 full-product matrices and innovative solutions that have been launched and will soon be launched in China. The solution will launch three global innovative products and future product pipelines that will be launched in China, covering the fields of breast cancer, blood oncology, neuroscience and chronic obstructive pulmonary disease.

"The CIIE is not only a window for China to adhere to high-level opening up to the outside world, but also an excellent stage for gathering global innovation. Roche has "checked in" the CIIE for seven consecutive years. Benefiting from the strong spillover effect of the CIIE, and leveraging the new drug review and approval system and related policies, many of the global innovative products exhibited by Roche have boarded the 'CIIE Express' and changed from 'exhibits' to 'commodities', fully demonstrating the 'speed of China' and benefiting more China patients faster." Bian Xin, President of Roche Pharmaceuticals China, said that this year coincides with the 30th anniversary of Roche Pharmaceuticals 'founding in China. Standing at a new starting point in our third year, we look forward to relying on the CIIE to continue to embrace openness and deepen cooperation, resonate with China's medical and health undertakings, and work together to write a colorful chapter.

Bian Xin, President of Roche Pharmaceuticals China

Innovative achievements are displayed in a concentrated manner, and three global products and future pipelines to be launched in China are unveiled

Innovation is deeply rooted in Roche's gene. Not long ago, Roche Pharmaceuticals released its Vision 2030 globally-"Addressing the Burden of Social Diseases with 20 Subversive Drugs", focusing on five key disease areas: anti-tumor, neuroscience, ophthalmology, immunity, cardiovascular and metabolism.

At this year's CIIE, Roche brought three global innovative products that will be launched in China, as well as a future product pipeline that includes innovations in diseases such as chronic obstructive pulmonary disease. In the field of breast cancer, Roche has brought Inavolisib, China's first and only PI3K α inhibitor, which is an innovative oral targeted therapeutic drug with the best potential in its class.

PI3K α inhibitor Inavolisib

It is understood that the PIK3CA mutation indicates a poor prognosis, accounting for a relatively high proportion of the China breast cancer population, reaching 46%, which is higher than the non-Asian population. Enalise is expected to bring more treatment options to adult patients with locally advanced or metastatic breast cancer with HR-positive and HER2 negative.

In the field of hematological oncology, Roche has demonstrated its rich product pipeline, including the innovative bispecific antibody drug gfeitumab approved during the CIIE last year, and Lunsumio (Mosunetuzumab), an innovative bispecific antibody drug that will soon be launched in China for the treatment of relapsed or refractory follicular lymphoma (FL). It is expected to provide FL patients with an effective, easily available, and fixed-cycle drug option, further promoting the development of lymphoma treatment.

In the field of neuroscience, Roche has brought the drug Ocrevus (Ocrelizumab) used to treat recurrent multiple sclerosis and primary progressive multiple sclerosis.

At the same time, Roche's future pipeline in China also made its debut on the CIIE stage, focusing on displaying the latest research and development results and future strategic directions in areas such as chronic obstructive pulmonary disease, cardiovascular disease, diabetes and metabolism that are constantly being increasingly deployed. According to WHO and the latest epidemiological data, COPD has become the third common cause of death in the world. There are also about 100 million COPD patients in China. The disease burden is heavy and there is huge unmet clinical needs in this field. This time, Roche brought the world's first fully humanized anti-ST2 monoclonal antibody Astegolimab. Its unique mechanism of action can bring benefits to a wider range of patients and is expected to become the first ST2 monoclonal antibody to treat chronic obstructive pulmonary disease.

Fully humanized anti-ST2 monoclonal antibody Astegolimab

In addition to showcasing global innovative products, Roche also brought more than 10 press conferences at the CIIE, covering cross-border cooperation in multiple fields such as digital medicine and improving the accessibility of innovative therapies, and working together with multiple partners to create a medical innovation ecosystem.

In addition, combining cutting-edge artificial intelligence and "black technologies" such as digitalization, Roche also brought Cyberarms coffee machines, early lung medical devices, etc. to this CIIE, and set up an anti-influenza interactive experience and fundus disease screening experience. Multiple immersive creative interactive areas such as experience create a new disease science experience for the audience that integrates technology, interest and futuristic sense.

Spillover effects bring "CIIE fruits" and accelerate benefits to China patients

The CIIE not only provides a platform for Roche to showcase its innovative achievements, but also helps Roche's innovative products and solutions complete the transformation from "exhibits" to "commodities" through its strong spillover effects and policy benefits, benefiting China patients faster and better. In the past two years, Roche has approved 16 innovative drugs and new indications for marketing in China.

Roche Pharmaceutical's China CIIE booth

After seven years of rushing to this "Eastern Covenant", Roche's many innovative products were approved for marketing in China during the CIIE or shortly after the exhibition, including the world's first breast cancer anti-HER2 dual target subcutaneous compound preparation Pertuzumab, which was exhibited last year, trastuzumab, the world's first innovative bispecific antibody drug targeting CD20/CD3 that acts on relapsed and refractory lymphoma, The world's first ophthalmic injection of bispecific antibody farrecizumab and corvalizumab, an innovative drug for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Among them, corvalizumab injection also successfully achieved its first launch in China, further demonstrating the spillover effect of the CIIE.

In addition, many of Roche's previous "CIIE babies" are also constantly introducing new ones. Roche's "CIIE star baby" Marbalosawei made his debut again at this CIIE. This innovative anti-influenza drug was included in the list of urgently needed clinical drugs overseas during the third CIIE, and was approved for marketing in China the following year. At present, this product not only achieves medical insurance coverage and supports online drug purchase by Internet hospitals, but also has been approved for children's indications and dry suspension.

"Sufuda has successfully achieved localized production this year, which will significantly shorten its global supply chain cycle, better meet the needs of China patients during the high influenza season, and help the development of China's public health." Bian Xin added.

In addition, Gfeitumab, born by Roche last year, is a novel bispecific antibody with a unique 2:1 structure used to treat adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have received at least two lines of systemic therapy. In June this year, starglo, the two-line indication data for gfeitumab, was released at the European Hematology Annual Meeting (EHA). Based on this data, China is expected to become one of the first countries in the world to approve this indication, benefiting more patients with relapsed and refractory lymphoma in China as soon as possible.

Over the past 30 years, we have continued to deepen cooperation and innovation to jointly build a better future for a healthy China

In March this year, the term "innovative drugs" entered the government work report for the first time; in July this year, the State Council executive meeting reviewed and approved the "Implementation Plan for the Full Chain to Support the Development of Innovative Drugs"; in addition, many achievements have been made in the research and development of innovative drugs in China. New breakthroughs and many new trends have emerged. Promoting the accelerated development of innovative drugs is inseparable from building an innovation ecosystem with win-win cooperation. Bian Xin said,"The CIIE not only provides an excellent platform for Roche to showcase its innovative achievements, but also builds a bridge for us to connect partners in the ecosystem to create opportunities and share the future."

China is Roche's strategic market, and Roche is very optimistic about China, a vibrant innovation hotspot. From the first multinational company to settle in Zhangjiang, Pudong, to the earliest establishment of a drug research and early development center in China, to the launch of Roche's China accelerator, from independent research and development to incubating local innovation, Roche continues to work with multiple partners to explore new cooperation models and accelerate the empowerment of local innovation.

Roche R & D has been rooted in China for 20 years. As Roche's first R & D center in emerging markets and the first drug R & D center wholly established by a multinational pharmaceutical company in Shanghai, Roche's China Innovation Center has undergone 20 years of "layer by layer" upgrades. At present, more than 320 patents have been obtained for inventions based on the center, and more than half of them have been granted patent authorizations in China, the United States, the European Union or Japan; in addition, 10 drug molecules have been advanced to the clinical trial stage.

In 2021, the Roche China accelerator with an investment of nearly 300 million yuan will be officially launched, focusing on innovative medical frontier fields such as drug research and development, diagnosis and personalized medicine, artificial intelligence (AI) and digital solutions, and accelerating the empowerment of local innovation. At present, nearly 20 local start-ups have emerged from hundreds of companies as accelerator member companies, and have reached 13 early R & D collaborations with Roche China Innovation Center to jointly explore new scientific directions and technology platforms.

In addition, Roche has also reached exclusive global cooperation with a number of local innovative pharmaceutical companies to jointly develop innovative therapeutic drugs in multiple oncology fields.

Looking to the future, Roche will continue to increase investment in China, continue to deepen the China market, comprehensively strengthen the end-to-end complete pharmaceutical value industry chain, upgrade localized production layout and investment, and allow Roche's innovative drugs to benefit more patients.